Name of the disease and condition studied: Chronic kidney disease in hemodialysis patients with secondary hyperparathyroidism. Chronic kidney disease (CKD)
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: Hemodialysis patients who received 3 mg of melatonin tablets per day, one hour before bedtime, for 12 weeks. Intervention 2: Control group: Hemo
Sponsors
Ahvaz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Over 18 years old Hemodialysis patients who have been on dialysis for at least three months PTH hormone level above 300 The presence of any active or chronic infection
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum PTH (parathyroid hormone) levels. Timepoint: Beginning of the study (before starting melatonin) End of week 12 (after 3 months of intervention). Method of measurement: Measurement with standard laboratory kits from Imam Hospital.;Serum vitamin D levels. Timepoint: Beginning of the study and end of week 12. Method of measurement: Venous blood sample, serum level determination with standard laboratory kit.;Serum levels of calcium, phosphorus, and magnesium. Timepoint: Beginning of the study and end of week 12. Method of measurement: Venous blood sample with standard laboratory kits.;Serum levels of other electrolytes. Timepoint: Beginning of the study and end of week 12. Method of measurement: Venous blood sample measurement with laboratory kits. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShahla Ahmadi Halili
Ahvaz University of Medical Sciences
Outcome results
None listed